Answers are grounded in this paper and cite their sources.
This commentary discusses the implications of ranolazine blocking late cardiac sodium current, particularly in the context of long QT syndrome 3 mutations.
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.
No takes yet. Share an insight, caveat, or question.
Makielski et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: